Been digging into Veeva Systems (VEEV) - wide moat SaaS name sitting 60 percent below targets with earnings next week. Thoughts?

The numbers on Veeva Systems feels like one of those quality setups that doesn’t get enough talk here. Most chase big tech hype but this one has the wide moat, steady free cash flow, and a catalyst coming that could move it fast.

Veeva builds cloud software for life sciences - CRM, compliance tools, and data platforms that pharma and biotech firms can’t live without. Switching costs are huge once integrated. Considerably wide moat and the retention numbers back it up.

Financials are solid. Full year revenue hit about $3.2b, up 16% with subscriptions growing 17%. Non-GAAP margins are in the mid 40s. Free cash flow has been strong and their latest guidance points to more of the same. They beat estimates consistently.

Stock sits around $158-$162 with a $26b market cap. Consensus targets are $260-$276, so 60%+ upside. Still rated Moderate Buy.

I’m watching Q1 earnings on June 3. These prints have popped nicely on beats and raises before. Plus the 2026 healthcare deregulation push could boost demand for efficiency tools. No tariff issues since it’s software.

Risks are there…competition from Salesforce or any pharma spending slowdown. Macro volatility could hit the multiple too. I’ve been adding on dips and plan to hold through earnings.